Conv. Plasma
Nigella Sativa
Peg.. Lambda

All remdesivir studies
Meta analysis
Home COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 66% Improvement Relative Risk Clearance half-life 29% primary Remdesivir  PLATCOV  EARLY TREATMENT  RCT Is early treatment with remdesivir beneficial for COVID-19? RCT 136 patients in multiple countries (September 2021 - June 2022) Improved viral clearance with remdesivir (p=0.000024) Jittamala et al., The J. Infectious Di.., Jul 2023 Favors remdesivir Favors control

Clinical antiviral efficacy of remdesivir in COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)

Jittamala et al., The Journal of Infectious Diseases, doi:10.1093/infdis/jiad275, PLATCOV, NCT05041907
Jul 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
High conflict of interest RCT with very low risk patients with high existing immunity, showing faster viral clearance with remdesivir. The viral clearance half-life was very short in both arms. With rapid viral clearance and very low risk patients, the trial favors detecting an effect with intravenous treatments that have rapid onset of action.
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir.
risk of hospitalization, 66.3% lower, RR 0.34, p = 1.00, treatment 0 of 67 (0.0%), control 1 of 69 (1.4%), NNT 69, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
relative clearance half-life, 28.9% better, RR 0.71, p < 0.001, treatment median 12.8 IQR 8.0 n=67, control median 18.0 IQR 10.5 n=69, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Jittamala et al., 20 Jul 2023, Randomized Controlled Trial, multiple countries, peer-reviewed, median age 30.1, 42 authors, study period 30 September, 2021 - 10 June, 2022, trial NCT05041907 (history) (PLATCOV).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperRemdesivirAll
Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)
Podjanee Jittamala, William H K Schilling, James A Watson, Viravarn Luvira, Tanaya Siripoon, Thundon Ngamprasertchai, Pedro J Almeida, Maneerat Ekkapongpisit, Cintia Cruz, James J Callery, Simon Boyd, Orawan Anunsittichai, Maliwan Hongsuwan, Yutatirat Singhaboot, Watcharee Pagornrat, Runch Tuntipaiboontana, Varaporn Kruabkontho, Thatsanun Ngernseng, Jaruwan Tubprasert, Mohammad Yazid Abdad, Srisuda Keayarsa, Wanassanan Madmanee, Renato S Aguiar, Franciele M Santos, Elizabeth M Batty, Pongtorn Hanboonkunupakarn, Borimas Hanboonkunupakarn, Sakol Sookprome, Kittiyod Poovorawan, Mallika Imwong, Walter R J Taylor, Vasin Chotivanich, Chunlanee Sangketchon, Wiroj Ruksakul, Kesinee Chotivanich, Sasithon Pukrittayakamee, Arjen M Dondorp, Nicholas P J Day, Mauro M Teixeira, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Nicholas J White, Nicholas J White, William Hk Schilling, Viravarn Luvira, James J Callery, Nicholas Pj Day, Sasithon Pukrittayakamee, Simon Boyd, Cintia Cruz, Arjen M Dondorp, Walter Rj Taylor, James A Watson, Watcharapong Piyaphanee, Kittiyod Poovorawan, Thundon Ngamprasertchai, Tanaya Siripoon, Borimas Hanboonkunupakarn, Kesinee Chotivanich, Podjanee Jittamala, Mallika Imwong, Maneerat Ekkapongpisit, Varaporn Kruabkontho, Thatsanun Ngernseng, Jaruwan Tubprasert, Mohammad Yazid Abdad, Srisuda Keayarsa, Orawan Anunsittichai, Maliwan Hongsuwan, Yutatirat Singhaboot, Wanassanan Madmanee, Elizabeth M Batty, Runch Tuntipaiboontana, Watcharee Pagornrat, Vasin Chotivanich, Wiroj Ruksakul, Chunlanee Sangketchon, Pongtorn Hanboonkunupakarn, Sakol Sookprome, Mauro M Teixeira, Pedro J Almeida, Renato S Aguiar, Franciele M Santos
The Journal of Infectious Diseases, doi:10.1093/infdis/jiad275
Background: Uncertainty over the therapeutic benefit provided by parenteral remdesivir in COVID-19 has resulted in varying treatment guidelines. Methods: In a multicenter open label, controlled, adaptive, pharmacometric platform trial, lowrisk adult patients with early symptomatic COVID-19 were randomized to one of eight treatment arms including intravenous remdesivir (200mg followed by 100mg daily for five days) or no study drug. The primary outcome was the rate of viral clearance (estimated under a linear model fit to the daily log10 viral densities, days 0-7) in standardized duplicate oropharyngeal swab eluates, in a modified intention-to-treat population (mITT). This ongoing adaptive trial is registered at (NCT05041907). Results: The two study arms enrolled 131 patients (remdesivir n=67, no study drug n=64) and estimated viral clearance rates from a median of 18 swab samples per patient (a total of 2356 qPCRs). Under the linear model, compared with the contemporaneous control arm (no study drug), remdesivir accelerated mean estimated SARS-CoV-2 viral clearance by 42% (95% credible interval [CI] 18 to 73). Interpretation: Parenteral remdesivir accelerates viral clearance in early symptomatic COVID-19. Pharmacometric assessment of therapeutics using the described method can rapidly and efficiently determine in vivo clinical efficacy.
Abd-Elsalam, Salama, Soliman, Naguib, Ibrahim et al., Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial, Am J Trop Med Hyg
Ader, Bouscambert-Duchamp, Hites, Peiffer-Smadja, Poissy et al., Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial, Lancet Infect Dis
Ali, Azher, Baqi, Borgia, Carrier et al., None, CMAJ
Beigel, Tomashek, Dodd, Mehta, Zingman et al., ACTT-1Study Group Members. Remdesivir for the Treatment of Covid-19 -Final Report, NEngl J Med
Bernal, Da Silva, Musungaie, Kovalchuk, Gonzalez et al., MOVe-OUT Study Group. Molnupiravir for Oral Treatment of Covid -19 in Nonhospitalized Patients, N Engl J Med
Fischer Wa 2nd, Eron, Jr, Holman, Cohen et al., A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus, Sci Transl Med
Goldman, Lye, Hui, Marks, Bruno et al., GS-US-540-5773 Investigators. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Gottlieb, Vaca, Paredes, Mera, Webb et al., Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients, N Engl J Med
Hammond, Leister-Tebbe, Gardner, Abreu, Wisemandle et al., EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, N Engl J Med
Lee, Murthy, Corpo, Senécal, Butler-Laporte et al., Remdesivir for the treatment of COVID-19: a systematic review and metaanalysis, Clin Microbiol Infect
Paules, Fauci, COVID-19: The therapeutic landscape, Med (N Y)
Schilling, Jittamala, Watson, Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, doi:10.7554/eLife.83201
Solera, Árbol, Bahinskaya, Marks, Humar et al., Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave, Am J Transplant, doi:10.1111/ajt.17199
Spinner, Gottlieb, Criner, López, Cattelan et al., GS-US-540-5774 Investigators. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial, JAMA
Wang, Zhang, Du, Du, Zhao et al., None, Lancet
Watson, Kissler, Day, Grad, White, Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies, Antimicrob Agents Chemother, doi:10.1128/aac.00192-22
Weinreich, Sivapalasingam, Norton, Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial, JAMA Netw Open
White, Strub-Wourgaft, Faiz, Guerin, Guidelines should not pool evidence from uncomplicated and severe COVID-19, Lancet
Who Solidarity, Consortium, Pan, Peto, Henao-Restrepo et al., None, N Engl J Med
Williamson, Feldmann, Schwarz, Meade-White, Porter et al., de Wit E. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop